The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients with early-stage non-small cell lung cancer (NSCLC). Published in the journal ...

When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows.

Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...

If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

Squamous cell carcinoma of the lung is linked to smoking and requires early detection and accurate staging for effective treatment. Diagnosis involves imaging and biopsy, with the TNM system used to ...

NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...

Deep-learning analysis of routine H&E slides accurately predicts key NSCLC driver mutations, supporting treatment in lung cancer care.

Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...